{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:19:17Z","timestamp":1793643557563,"version":"4.5.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02361373"],"award-info":[{"award-number":["RF-2016-02361373"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["ER2017 2364984-ERANET"],"award-info":[{"award-number":["ER2017 2364984-ERANET"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG18451"],"award-info":[{"award-number":["IG18451"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alleanza Contro il Cancro, ACC Genomics - WG Sarcomi"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Standard therapy of osteosarcoma (OS) and Ewing sarcoma (EW) rests on cytotoxic regimes, which are largely unsuccessful in advanced patients. Preclinical models are needed to break this impasse. A panel of patient-derived xenografts (PDX) was established by implantation of fresh, surgically resected osteosarcoma (OS) and Ewing sarcoma (EW) in NSG mice. Engraftment was obtained in 22 of 61 OS (36%) and 7 of 29 EW (24%). The success rate in establishing primary cell cultures from OS was lower than the percentage of PDX engraftment in mice, whereas the reverse was observed for EW; the implementation of both<jats:italic>in vivo<\/jats:italic>and<jats:italic>in vitro<\/jats:italic>seeding increased the proportion of patients yielding at least one workable model. The establishment of<jats:italic>in vitro<\/jats:italic>cultures from PDX was highly efficient in both tumor types, reaching 100% for EW. Morphological and immunohistochemical (SATB2, P-glycoprotein 1, CD99, caveolin 1) studies and gene expression profiling showed a remarkable similarity between patient\u2019s tumor and PDX, which was maintained over several passages in mice, whereas cell cultures displayed a lower correlation with human samples. Genes differentially expressed between OS original tumor and PDX mostly belonged to leuykocyte-specific pathways, as human infiltrate is gradually replaced by murine leukocytes during growth in mice. In EW, which contained scant infiltrates, no gene was differentially expressed between the original tumor and the PDX. A novel therapeutic combination of anti-CD99 diabody C7 and irinotecan was tested against two EW PDX; both drugs inhibited PDX growth, the addition of anti-CD99 was beneficial when chemotherapy alone was less effective. The panel of OS and EW PDX faithfully mirrored morphologic and genetic features of bone sarcomas, representing reliable models to test therapeutic approaches.<\/jats:p>","DOI":"10.1038\/s41598-019-48634-y","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T10:03:05Z","timestamp":1566381785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations"],"prefix":"10.1038","volume":"9","author":[{"given":"Patrizia","family":"Nanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Landuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Manara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Cristalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Pasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Carrabotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1595-6887","authenticated-orcid":false,"given":"Manuela","family":"Ferracin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna L.","family":"Ianzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Maria","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Picci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier-Luigi","family":"Lollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Scotlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,21]]},"reference":[{"key":"48634_CR1","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/cncr.30589","volume":"123","author":"DR Reed","year":"2017","unstructured":"Reed, D. R. et al. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 123, 2206\u201318 (2017).","journal-title":"Cancer."},{"key":"48634_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.mayocp.2012.01.015","volume":"87","author":"CAS Arndt","year":"2012","unstructured":"Arndt, C. A. S., Rose, P. S., Folpe, A. L. & Laack, N. N. Common musculoskeletal tumors of childhood and adolescence. Mayo Clin Proc. 87, 475\u201387 (2012).","journal-title":"Mayo Clin Proc."},{"key":"48634_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1517\/14728214.2015.1051965","volume":"20","author":"CM Hattinger","year":"2015","unstructured":"Hattinger, C. M. et al. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs. 20, 495\u2013514 (2015).","journal-title":"Expert Opin Emerg Drugs."},{"key":"48634_CR4","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","volume":"33","author":"N Gaspar","year":"2015","unstructured":"Gaspar, N. et al. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. J Clin Oncol. 33, 3036\u201346 (2015).","journal-title":"J Clin Oncol."},{"key":"48634_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1200\/JCO.2017.74.7402","volume":"36","author":"AS Pappo","year":"2018","unstructured":"Pappo, A. S. & Dirksen, U. Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas. J Clin Oncol. 36, 168\u201379 (2018).","journal-title":"J Clin Oncol."},{"key":"48634_CR6","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/annonc\/mdp502","volume":"21","author":"P Picci","year":"2010","unstructured":"Picci, P. et al. Survival in high-grade osteosarcoma: Improvement over 21 years at a single institution. Ann Oncol. 21, 1366\u201373 (2010).","journal-title":"Ann Oncol."},{"key":"48634_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0300891617753257","volume":"104","author":"E Tirtei","year":"2017","unstructured":"Tirtei, E. et al. Survival after Second and Subsequent Recurrences in Osteosarcoma: A Retrospective Multicenter Analysis. Tumori. 104, 202\u2013206 (2017).","journal-title":"Tumori."},{"key":"48634_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nrc.2016.140","volume":"17","author":"AT Byrne","year":"2017","unstructured":"Byrne, A. T. et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 17, 254\u201368 (2017).","journal-title":"Nat Rev Cancer."},{"key":"48634_CR9","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo, M. et al. Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 4, 998\u20131013 (2014).","journal-title":"Cancer Discov."},{"key":"48634_CR10","doi-asserted-by":"publisher","first-page":"18708","DOI":"10.1073\/pnas.1111840108","volume":"108","author":"J-P Gillet","year":"2011","unstructured":"Gillet, J.-P. et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA 108, 18708\u201313 (2011).","journal-title":"Proc Natl Acad Sci USA"},{"key":"48634_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fonc.2016.00039","volume":"6","author":"TGP Gr\u00fcnewald","year":"2016","unstructured":"Gr\u00fcnewald, T. G. P. & Fulda, S. Editorial: Biology-Driven Targeted Therapy of Pediatric Soft-Tissue and Bone Tumors: Current Opportunities and Future Challenges. Front Oncol. 6, 39 (2016).","journal-title":"Front Oncol."},{"key":"48634_CR12","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1158\/0008-5472.CAN-08-4041","volume":"69","author":"JL Ord\u00f3\u00f1ez","year":"2009","unstructured":"Ord\u00f3\u00f1ez, J. L., Osuna, D., Herrero, D., Alava, Ede & Madoz-G\u00farpide, J. Advances in Ewing\u2019s sarcoma research: Where are we now and what lies ahead? Cancer Res. 69, 7140\u201350 (2009).","journal-title":"Cancer Res."},{"key":"48634_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2017.307","volume":"50","author":"J Jung","year":"2018","unstructured":"Jung, J., Seol, H. S. & Chang, S. The Generation and Application of Patient-Derived Xenograft Model for Cancer Research. Cancer Res Treat. 50, 1\u201310 (2018).","journal-title":"Cancer Res Treat."},{"key":"48634_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature.2016.19364","volume":"530","author":"H Ledford","year":"2016","unstructured":"Ledford, H. US cancer institute to overhaul tumour cell lines. Nature. 530, 391 (2016).","journal-title":"Nature."},{"key":"48634_CR15","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","volume":"73","author":"D Siolas","year":"2013","unstructured":"Siolas, D. & Hannon, G. J. Patient-derived tumor xenografts: Transforming clinical samples into mouse models. Cancer Res. 73, 5315\u20139 (2013).","journal-title":"Cancer Res."},{"key":"48634_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13046-016-0462-4","volume":"35","author":"L Pompili","year":"2016","unstructured":"Pompili, L., Porru, M., Caruso, C., Biroccio, A. & Leonetti, C. Patient-derived xenografts: A relevant preclinical model for drug development. J Exp Clin Cancer Res. 35, 189 (2016).","journal-title":"J Exp Clin Cancer Res."},{"key":"48634_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1487-6","volume":"16","author":"W Lu","year":"2018","unstructured":"Lu, W., Chao, T., Ruiqi, C., Juan, S. & Zhihong, L. Patient-derived xenograft models in musculoskeletal malignancies. J Transl Med. 16, 107 (2018).","journal-title":"J Transl Med."},{"key":"48634_CR18","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","volume":"28","author":"E Izumchenko","year":"2017","unstructured":"Izumchenko, E. et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol. 28, 2595\u2013605 (2017).","journal-title":"Ann Oncol."},{"key":"48634_CR19","first-page":"1","volume":"324","author":"T Nomura","year":"2008","unstructured":"Nomura, T., Tamaoki, N., Takakura, A. & Suemizu, H. Basic concept of development and practical application of animal models for human diseases. Curr Top Microbiol Immunol. 324, 1\u201324 (2008).","journal-title":"Curr Top Microbiol Immunol."},{"key":"48634_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/1097-0215(20000801)87:3<328::AID-IJC4>3.0.CO;2-1","volume":"87","author":"K Scotlandi","year":"2000","unstructured":"Scotlandi, K. et al. Identification of EWS\/FLI-1 transcripts in giant-cell tumor of bone. Int J Cancer. 87, 328\u201335 (2000).","journal-title":"Int J Cancer."},{"key":"48634_CR21","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1007\/s00253-015-7226-5","volume":"100","author":"D Moricoli","year":"2016","unstructured":"Moricoli, D. et al. Process development of a human recombinant diabody expressed in E. coli: Engagement of CD99-induced apoptosis for target therapy in Ewing\u2019s sarcoma. Appl Microbiol Biotechnol. 100, 3949\u201363 (2016).","journal-title":"Appl Microbiol Biotechnol."},{"key":"48634_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/13577140020008084","volume":"4","author":"MD McCarter","year":"2000","unstructured":"McCarter, M. D., Lewis, J. J., Antonescu, C. R. & Brennan, M. F. Extraskeletal osteosarcoma: Analysis of outcome of a rare neoplasm. Sarcoma. 4, 119\u201323 (2000).","journal-title":"Sarcoma."},{"key":"48634_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0920-8","volume":"19","author":"J Yu","year":"2017","unstructured":"Yu, J. et al. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Breast Cancer Res. 19, 130 (2017).","journal-title":"Breast Cancer Res."},{"key":"48634_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.neo.2015.09.004","volume":"17","author":"G Bondarenko","year":"2015","unstructured":"Bondarenko, G. et al. Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors. Neoplasia. 17, 735\u201341 (2015).","journal-title":"Neoplasia."},{"key":"48634_CR25","doi-asserted-by":"publisher","first-page":"e39294","DOI":"10.1371\/journal.pone.0039294","volume":"7","author":"K Chen","year":"2012","unstructured":"Chen, K., Ahmed, S., Adeyi, O., Dick, J. E. & Ghanekar, A. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PLoS ONE. 7, e39294 (2012).","journal-title":"PLoS ONE."},{"key":"48634_CR26","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1158\/1078-0432.CCR-05-1824","volume":"12","author":"J Vakkila","year":"2006","unstructured":"Vakkila, J., Jaffe, R., Michelow, M. & Lotze, M. T. Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: A major nosologic difference with adult tumors. Clin Cancer Res. 12, 2049\u201354 (2006).","journal-title":"Clin Cancer Res."},{"key":"48634_CR27","doi-asserted-by":"publisher","first-page":"e0175574","DOI":"10.1371\/journal.pone.0175574","volume":"12","author":"G Fourcade","year":"2017","unstructured":"Fourcade, G. et al. Evolution of EBV seroprevalence and primary infection age in a French hospital and a city laboratory network, 2000\u20132016. PLoS ONE. 12, e0175574 (2017).","journal-title":"PLoS ONE."},{"key":"48634_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature23647","volume":"549","author":"E Stewart","year":"2017","unstructured":"Stewart, E. et al. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature. 549, 96\u2013100 (2017).","journal-title":"Nature."},{"key":"48634_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nature23101","volume":"548","author":"R Dienstmann","year":"2017","unstructured":"Dienstmann, R. & Tabernero, J. Cancer: A precision approach to tumour treatment. Nature. 548, 40\u20131 (2017).","journal-title":"Nature."},{"key":"48634_CR30","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1158\/2159-8290.CD-14-0622","volume":"4","author":"F Tirode","year":"2014","unstructured":"Tirode, F. et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov. 4, 1342\u201353 (2014).","journal-title":"Cancer Discov."},{"key":"48634_CR31","doi-asserted-by":"publisher","first-page":"598704","DOI":"10.1155\/2011\/598704","volume":"2011","author":"AA Kowalewski","year":"2011","unstructured":"Kowalewski, A. A., Randall, R. L. & Lessnick, S. L. Cell Cycle Deregulation in Ewing\u2019s Sarcoma Pathogenesis. Sarcoma. 2011, 598704 (2011).","journal-title":"Sarcoma."},{"key":"48634_CR32","first-page":"3405","volume":"37","author":"C Chao","year":"2017","unstructured":"Chao, C. et al. Patient-derived Xenografts from Colorectal Carcinoma: A Temporal and Hierarchical Study of Murine Stromal Cell Replacement. Anticancer Res. 37, 3405\u201312 (2017).","journal-title":"Anticancer Res."},{"key":"48634_CR33","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/ijc.30778","volume":"141","author":"J Smida","year":"2017","unstructured":"Smida, J. et al. Genome-wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma. Int J Cancer. 141, 816\u201328 (2017).","journal-title":"Int J Cancer."},{"key":"48634_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bone.2016.10.017","volume":"102","author":"K Rickel","year":"2017","unstructured":"Rickel, K., Fang, F. & Tao, J. Molecular genetics of osteosarcoma. Bone. 102, 69\u201379 (2017).","journal-title":"Bone."},{"key":"48634_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/1078-0432.CCR-14-0492","volume":"21","author":"C Guerzoni","year":"2015","unstructured":"Guerzoni, C. et al. CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin. Clin Cancer Res. 21, 146\u201356 (2015).","journal-title":"Clin Cancer Res."},{"key":"48634_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2174\/1389201011314040011","volume":"14","author":"M Gellini","year":"2013","unstructured":"Gellini, M. et al. Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing\u2019s sarcoma tumor cells. Curr Pharm Biotechnol. 14, 449\u201363 (2013).","journal-title":"Curr Pharm Biotechnol."},{"key":"48634_CR37","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1080\/0284186X.2018.1449250","volume":"57","author":"E Palmerini","year":"2018","unstructured":"Palmerini, E. et al. Irinotecan and temozolomide in recurrent Ewing sarcoma: An analysis in 51 adult and pediatric patients. Acta Oncol. 57, 958\u201364 (2018).","journal-title":"Acta Oncol."},{"key":"48634_CR38","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1158\/1078-0432.CCR-12-0372","volume":"18","author":"S Julien","year":"2012","unstructured":"Julien, S. et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res. 18, 5314\u201328 (2012).","journal-title":"Clin Cancer Res."},{"key":"48634_CR39","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","volume":"1","author":"A Bertotti","year":"2011","unstructured":"Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508\u201323 (2011).","journal-title":"Cancer Discov."},{"key":"48634_CR40","doi-asserted-by":"crossref","first-page":"62533","DOI":"10.18632\/oncotarget.11530","volume":"7","author":"J Jung","year":"2016","unstructured":"Jung, J. et al. Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. Oncotarget. 7, 62533\u201346 (2016).","journal-title":"Oncotarget."},{"key":"48634_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-168","volume":"11","author":"X-c Zhang","year":"2013","unstructured":"Zhang, X.-c et al. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: Useful tools for preclinical studies of targeted therapies. J Transl Med. 11, 168 (2013).","journal-title":"J Transl Med."},{"key":"48634_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3892\/or.2013.2434","volume":"30","author":"Z-H Li","year":"2013","unstructured":"Li, Z.-H. et al. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer. Oncol Rep. 30, 499\u2013505 (2013).","journal-title":"Oncol Rep."},{"key":"48634_CR43","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-07-0078","volume":"13","author":"E Marangoni","year":"2007","unstructured":"Marangoni, E. et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 13, 3989\u201398 (2007).","journal-title":"Clin Cancer Res."},{"key":"48634_CR44","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-12-4081","volume":"73","author":"X Zhang","year":"2013","unstructured":"Zhang, X. et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 73, 4885\u201397 (2013).","journal-title":"Cancer Res."},{"key":"48634_CR45","doi-asserted-by":"publisher","first-page":"6980","DOI":"10.1158\/0008-5472.CAN-14-0274","volume":"74","author":"F Ricci","year":"2014","unstructured":"Ricci, F. et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 74, 6980\u201390 (2014).","journal-title":"Cancer Res."},{"key":"48634_CR46","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.molonc.2014.01.008","volume":"8","author":"MD Topp","year":"2014","unstructured":"Topp, M. D. et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol. 8, 656\u201368 (2014).","journal-title":"Mol Oncol."},{"key":"48634_CR47","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ygyno.2015.07.104","volume":"139","author":"J Depreeuw","year":"2015","unstructured":"Depreeuw, J. et al. Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. Gynecol Oncol. 139, 118\u201326 (2015).","journal-title":"Gynecol Oncol."},{"key":"48634_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ydbio.2015.03.001","volume":"411","author":"E Stewart","year":"2016","unstructured":"Stewart, E. et al. The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. Dev Biol. 411, 287\u201393 (2016).","journal-title":"Dev Biol."},{"key":"48634_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF03033741","volume":"10","author":"S Bruheim","year":"2004","unstructured":"Bruheim, S., Bruland, O. S., Breistol, K., Maelandsmo, G. M. & Fodstad, O. Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res. 10, 133\u201341 (2004).","journal-title":"Pathol Oncol Res."},{"key":"48634_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-125","volume":"10","author":"DJ Monsma","year":"2012","unstructured":"Monsma, D. J. et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med. 10, 125 (2012).","journal-title":"J Transl Med."},{"key":"48634_CR51","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.celrep.2014.09.028","volume":"9","author":"E Stewart","year":"2014","unstructured":"Stewart, E. et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 9, 829\u201341 (2014).","journal-title":"Cell Rep."},{"key":"48634_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0497-x","volume":"13","author":"C Blattmann","year":"2015","unstructured":"Blattmann, C. et al. Establishment of a patient-derived orthotopic osteosarcoma mouse model. J Transl Med. 13, 136 (2015).","journal-title":"J Transl Med."},{"key":"48634_CR53","doi-asserted-by":"crossref","first-page":"e27579","DOI":"10.1002\/pbc.27579","volume":"66","author":"N Rainusso","year":"2019","unstructured":"Rainusso, N. et al. Generation of patient-derived tumor xenografts from percutaneous tumor biopsies in children with bone sarcomas. Pediatr Blood Cancer. 66, e27579 (2019).","journal-title":"Pediatr Blood Cancer."},{"key":"48634_CR54","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/labinvest.2013.92","volume":"93","author":"SA Williams","year":"2013","unstructured":"Williams, S. A., Anderson, W. C., Santaguida, M. T. & Dylla, S. J. Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab Invest. 93, 970\u201382 (2013).","journal-title":"Lab Invest."},{"key":"48634_CR55","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-08-4210","volume":"69","author":"VC Daniel","year":"2009","unstructured":"Daniel, V. C. et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 69, 3364\u201373 (2009).","journal-title":"Cancer Res."},{"key":"48634_CR56","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bbrc.2005.05.097","volume":"333","author":"H-J Hausser","year":"2005","unstructured":"Hausser, H.-J. & Brenner, R. E. Phenotypic instability of Saos-2 cells in long-term culture. Biochem Biophys Res Commun. 333, 216\u201322 (2005).","journal-title":"Biochem Biophys Res Commun."},{"key":"48634_CR57","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/d41586-018-05890-8","volume":"560","author":"C Willyard","year":"2018","unstructured":"Willyard, C. The mice with human tumours: Growing pains for a popular cancer model. Nature. 560, 156\u20137 (2018).","journal-title":"Nature."},{"key":"48634_CR58","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/ng.3967","volume":"49","author":"U Ben-David","year":"2017","unstructured":"Ben-David, U. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 49, 1567\u201375 (2017).","journal-title":"Nat Genet."},{"key":"48634_CR59","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nm.4404","volume":"23","author":"Editorial","year":"2017","unstructured":"Editorial. Children first. Nat Med. 23, 1005 (2017).","journal-title":"Nat Med."},{"key":"48634_CR60","first-page":"142","volume":"3","author":"BW Sch\u00e4fer","year":"2013","unstructured":"Sch\u00e4fer, B. W., Koscielniak, E., Kovar, H. & Fulda, S. ESF-EMBO Symposium \u201cMolecular Biology and Innovative Therapies in Sarcomas of Childhood and Adolescence\u201d Sept 29\u2013Oct 4. Polonia Castle Pultusk, Poland. Front Oncol. 3, 142 (2013).","journal-title":"Polonia Castle Pultusk, Poland. Front Oncol."},{"key":"48634_CR61","doi-asserted-by":"publisher","first-page":"43062","DOI":"10.18632\/oncotarget.9657","volume":"7","author":"SR Ambati","year":"2016","unstructured":"Ambati, S. R. et al. BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models. Oncotarget. 7, 43062\u201375 (2016).","journal-title":"Oncotarget."},{"key":"48634_CR62","doi-asserted-by":"publisher","first-page":"18875","DOI":"10.18632\/oncotarget.4303","volume":"6","author":"JL Ord\u00f3\u00f1ez","year":"2015","unstructured":"Ord\u00f3\u00f1ez, J. L. et al. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget. 6, 18875\u201390 (2015).","journal-title":"Oncotarget."},{"key":"48634_CR63","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/ijc.30792","volume":"141","author":"M Xian","year":"2017","unstructured":"Xian, M. et al. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2\u03b1\/ATF4\/CHOP axis. Int J Cancer. 141, 1029\u201341 (2017).","journal-title":"Int J Cancer."},{"key":"48634_CR64","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/cncr.28696","volume":"120","author":"J Stebbing","year":"2014","unstructured":"Stebbing, J. et al. Patient-derived xenografts for individualized care in advanced sarcoma. Cancer. 120, 2006\u201315 (2014).","journal-title":"Cancer."},{"key":"48634_CR65","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1158\/1535-7163.MCT-17-0818","volume":"17","author":"MC Manara","year":"2018","unstructured":"Manara, M. C. et al. A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. Mol Cancer Ther. 17, 1881\u201392 (2018).","journal-title":"Mol Cancer Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48634-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48634-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48634-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T09:34:49Z","timestamp":1695116089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48634-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,21]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48634"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48634-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,21]]},"assertion":[{"value":"17 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M. Magnani holds shares in Diatheva SrL. The company has an exclusive licence on a patent protecting dAbd C7 antibody. All other authors declare no potential conflict of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12174"}}